ReNAgade has developed an extensive and complementary platform that integrates its exclusive delivery technologies, such as innovative lipid nanoparticles (LNPs), with a diverse range of coding, editing, and gene insertion tools, all within a comprehensive RNA system
The funding round was spearheaded by MPM BioImpact and F2 Ventures. (Credit: THAVIS 3D on Unsplash)
ReNAgade Therapeutics, a company harnessing the boundless potential of RNA medicines to treat diseases, has recently disclosed a Series A funding round of $300 million. This significant investment was spearheaded by MPM BioImpact and F2 Ventures, underscoring the confidence in ReNAgade’s mission and prospects.
ReNAgade has developed an extensive and complementary platform that integrates its exclusive delivery technologies, such as innovative lipid nanoparticles (LNPs), with a diverse range of coding, editing, and gene insertion tools, all within a comprehensive RNA system.
The primary objective of ReNAgade is to tackle significant limitations in RNA therapeutics by facilitating the delivery of RNA medicines to previously unreachable tissues and cells in the body.
This breakthrough capability expands the potential market for addressing various diseases. Notably, the company has formed a successful Joint Venture with Orna Therapeutics Inc., merging ReNAgade’s delivery platform with Orna’s circular RNA technology. As a result, Orna has established a collaboration with Merck, which encompasses the utilization of technologies developed under the Orna/ReNAgade JV.
MPM Bioimpact Managing Partner and ReNAgade founder Ansbert Gadicke said: “ReNAgade was founded on a bold idea – to dramatically transcend the boundaries of RNA medicine, a field that has made great strides but remains in its infancy.
“By innovating on delivery technology and bringing an array of genomic medicine tools under one roof, ReNAgade is poised to deliver RNA to organs and tissues not previously accessible. ReNAgade’s joint venture with Orna provides early validation of the technologies that ReNAgade will continue to bring forward.”
ReNAgade is a biotech company founded by MPM BioImpact and led by Chairman and CEO Amit D. Munshi. Amit Munshi is an industry veteran with over 30 years of experience in leading biotech companies. Prior to joining ReNAgade, he served as the CEO of Arena Pharmaceuticals.
The company is supported by a strong executive and scientific team with expertise in various RNA modalities. Dr. Pete Smith, the Chief Scientific Officer and an Executive Partner at MPM BioImpact, brings his experience from Alnylam, where he previously held the position of Chief Early Development Officer. Before that, he served as Senior Vice President and Head of R&D Nonclinical at Moderna.
Dr. Ciaran Lawlor is the Chief Operating Officer of ReNAgade. He joined the company from the Boston Consulting Group, where he worked as a consultant. Prior to that, he held several scientific roles at Moderna.
Brian Shuster is the Chief Business Officer of ReNAgade. He joined the company from Bristol Myers Squibb and has previous experience at Johnson & Johnson, where he led acquisitions, divestitures, and equity investing. He also worked at J.P. Morgan, where he assisted biotech companies with strategic and financing transactions.
ReNAgade CEO Amit D. Munshi said: “In order to fulfill our mission to develop RNA medicines with the potential to treat any disease anywhere in the body, we have curated a world-class, multidisciplinary team who have collectively achieved 25 NDAs, including four in RNA medicines, and 200 INDs, and have been pioneers in the field of RNA medicines.
“We are further buoyed by the support of our long-term investors and validated by the progress we have made to date – making us well-positioned to expand the reach of RNA medicine far beyond what was previously thought possible.”